<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>dolutegravir-based &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/dolutegravir-based/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 18 Oct 2026 01:03:00 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>dolutegravir-based &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>One in five on dolutegravir HIV therapy in East Africa shows hyperglycemia</title>
		<link>https://bioengineer.org/one-in-five-on-dolutegravir-hiv-therapy-in-east-africa-shows-hyperglycemia/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sun, 18 Oct 2026 01:03:00 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[adults]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[antiretroviral]]></category>
		<category><![CDATA[associated]]></category>
		<category><![CDATA[dolutegravir-based]]></category>
		<category><![CDATA[East]]></category>
		<category><![CDATA[factors]]></category>
		<category><![CDATA[hyperglycemia]]></category>
		<category><![CDATA[living]]></category>
		<category><![CDATA[Review]]></category>
		<category><![CDATA[Systematic]]></category>
		<category><![CDATA[therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=433287</guid>

					<description><![CDATA[Dolutegravir has transformed HIV care across the world. The integrase strand transfer inhibitor is potent, has a high genetic barrier to resistance, and is now the backbone of first-line antiretroviral therapy in most countries, including much of East Africa where]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">433287</post-id>	</item>
	</channel>
</rss>
